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Human African trypanosomiasis of the CNS: 
current issues and challenges
Peter G.E. Kennedy
Department of Neurology, Division of Clinical Neurosciences, University of Glasgow, Institute of Neurological Sciences,
Southern General Hospital, Glasgow, Scotland, United Kingdom
Human African trypanosomiasis (HAT), also known as sleeping sickness, is a major cause of mortality
and morbidity in sub-Saharan Africa. Current therapy with melarsoprol for CNS HAT has unacceptable
side-effects with an overall mortality of 5%. This review discusses the issues of diagnosis and staging of
CNS disease, its neuropathogenesis, and the possibility of new therapies for treating late-stage disease.
J. Clin. Invest. 113:496–504 (2004). doi:10.1172/JCI200421052.
sickness. In 1903, Aldo Castellani, working with Bruce,
identified trypanosomes in the blood and cerebrospinal
fluid (CSF) of a patient with sleeping sickness (2, 3), and
in 1910 J.W.W. Stephens and H.B. Fantham first
described Trypanosoma brucei rhodesiense (2), which is
now recognized as causing East African sleeping sick-
ness. There are characteristic differences between the
biology and clinical features of T.b. gambiense disease and
T.b. rhodesiense disease, probably due to a greater adap-
tation of the gambiense parasite to humans.
Currently, HAT occurs in 36 countries in sub-Saharan
Africa; about 60 million people worldwide are at risk
from developing the disease (4). The annual incidence
of the disease is approximately 300,000 cases, and the
area of Africa that is infested by the tsetse fly encom-
passes approximately ten million square kilometers (2,
5) — a third of the land mass of Africa (Figure 1). HAT
was almost brought under control during the early
1950s (6), with a significant decrease in the number of
newly registered cases from 1949 to 1965, but a variety
of factors led to its recent reemergence. These include
socio-economic unrest — especially war — causing dis-
ruption of disease surveillance and control, inadequate
financial allocation of critical resources to the disease
during peacetime, increasing parasite drug resistance,
changes in climate and vegetation, the emergence of
new virulent parasite strains, unpredicted population
movements of animal reservoirs, and changes in host
disease susceptibility (5, 6). Many of these factors may
operate simultaneously, and there have been several sig-
nificant epidemics and focal resurgences of the disease
in various regions of Africa in recent years.
Trypanosome biology
In both types of HAT the disease is transmitted by the
blood-sucking tsetse fly of the genus Glossina. Infected
wild animals and domestic animals, such as cattle, are
the reservoirs of parasites causing human disease. The
Historical perspective
Human African trypanosomiasis (HAT), also known as
sleeping sickness, comes in two variants: East African
and West African. Caused by protozoan parasites of the
genus Trypanosoma, it has emerged over the last few
decades as a major threat to human health in Africa.
While for centuries there was an awareness of the dis-
ease and of its propensity to induce a fatal sleep disor-
der, it was not until the period 1894–1910 that the cause
of sleeping sickness in humans and cattle was discov-
ered. Preeminent in this discovery was David Bruce,
who, while working in Zululand on a wasting disease of
cattle known as nagana, identified trypanosomes in the
blood of affected cattle (1, 2). He then established exper-
imentally that healthy game animals were host reser-
voirs of the disease, which was transmitted by the bite
of the tsetse fly to domestic animals, which then became
ill (2). In 1899 the causative parasite was identified as
Trypanosoma brucei, and in 1902 Everett Dutton first
identified, in a European patient, a subspecies of try-
panosomes called Trypanosoma brucei gambiense (2) that
is now recognized as the cause of West African sleeping
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flies become infective approximately 21 days after feed-
ing on an infected animal host (5). The fly ingests the
trypanosomes during a blood meal from the infected
animal, following which the parasites undergo a series
of morphological and biochemical changes in the fly’s
anterior midgut where the infection is initially estab-
lished (7). Long slender parasitic forms produced in the
midgut then move to the salivary glands to become epi-
mastigotes, which then change into short stumpy
infective metacyclic trypanosomes which enter via the
wound of a bitten individual. A primary lesion known
as a trypanosomal chancre usually develops 5–15 days
later at the site of the bite, soon after which the try-
panosomes invade the bloodstream, lymph nodes, and
other tissues. HAT is invariably fatal if untreated. A fly
remains infective for life, and human/fly contact is
therefore a crucial component of the disease. The life
cycle of the organism in the human and the tsetse fly is
summarized in Figure 2.
Much work has been carried out on the sequencing and
mapping of the trypanosome genome (8). Trypanosomes
causing HAT are diploid and have a haploid nuclear DNA
content of approximately 35 Mb (8, 9). Three classes of
chromosome in T. brucei have been identified based on
size, namely megabase (1–6 Mb), of which there are at
least 11, intermediate (200–900 kb), and at least 100
minichromosomes (50–150 kb) (8, 9). The entire genome
contains about 10,000 genes, 10% of which are thought
to be variant surface glycoprotein (VSG) genes encoding
variable surface glycoproteins (9). The VSG genes are of
great pathogenic importance as they provide the molec-
ular basis for the antigenic variation seen in trypanosome
infection, and only one of them is expressed at any one
time, the rest being transcriptionally silent (9). The VSGs
are distributed over the surface of the trypanosome and
are anchored to the outer membrane by a glycosylphos-
phatidylinositol (GPI) anchor (9). Ten million copies of a
single species of VSG cover the trypanosome surface at
any one time. During infection of the host, a constant low
frequency gene conversion process switches transcrip-
tionally inactive basic copy VSG genes in and out of the
expression site, and this antigenic variation allows the
parasite to continuously evade the host’s immune
response. As a result, the parasite undergoes rapid multi-
plication in the blood of the host, producing waves of
parasitaemia that characterize this disease (10).
Clinical features
There are two recognized stages in the clinical presenta-
tion of HAT, namely the early hemolymphatic stage, and
the late encephalitic stage when the CNS is involved.
However, the transition from the early to the late stage is
not always distinct in rhodesiense infection (5). The tempo
of the disease is usually acute in rhodesiense disease —
CNS invasion by the parasite occurs early, within a few
months after initial infection — whereas gambiense infec-
tion is usually a slower, chronic infection, with late CNS
infection lasting months to years.
Early (hemolymphatic) stage. The onset is variable but
usually occurs 1–3 weeks after the bite. Episodes of
fever lasting 1–7 days occur together with generalized
lymphadenopathy. The early symptoms tend to be non-
specific: malaise, headache, arthralgia, generalized
weakness, and weight loss (11). Multiple organs may
then be infected (5, 12), including the spleen, liver, skin,
cardiovascular system, endocrine system, and eyes. This
involvement underlies the wide spectrum of systemic
dysfunction that may occur (5).
Late (encephalitic) stage. The onset is insidious and the
potential clinical phenotype is wide (5, 12). The broad
neurologic spectrum has been detailed elsewhere (5), and
the reported features can be grouped into general cate-
gories such as psychiatric, motor, and sensory abnor-
malities, and sleep disturbances. The mental distur-
bances may be subtle, and include irritability, lassitude,
headache, apparent personality changes, and overt psy-
chiatric presentations such as violence, hallucinations,
suicidal tendencies, and mania (5, 12). Motor system
involvement may include limb tremors, tongue and limb
muscle fasciculation, limb hypertonia and pyramidal
weakness, choreiform and athetoid movements,
dysarthria, cerebellar ataxia, and polyneuritis (5, 13).
Pout and palmar-mental reflexes may also be present.
Sensory involvement may manifest as painful hyperaes-
thesia, pruritis, and also deep hyperaesthesia (Kerandel’s
sign), the latter being reported as particularly common
in Europeans (12). The characteristic sleep disturbances
Figure 1
Diagrammatic representation of the distribution of the two types of
human African trypanosomiasis in Africa. Figure modified with per-
mission from Butterworth-Heinemann (5).
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include lassitude, distractibility, and spontaneous,
uncontrollable urges to sleep, along with a reversal of the
normal sleep-wake cycle in which daytime somnolence
alternates with nocturnal insomnia. While these various
features, including the sleep abnormalities, are typical of
HAT, they are not individually diagnostic, since some of
them may also be seen during other CNS infections. If
untreated, the patient progresses to the final stage of the
disease, which is characterized by seizures, severe som-
nolence, double incontinence, cerebral edema, coma, sys-
temic organ failure, and inevitable death.
Disease diagnosis
The diagnosis of HAT is based on a combination of
clinical and investigative data. A typical clinical pres-
entation in the context of a geographical location
where HAT is known to be endemic is clearly the key
diagnostic clue. However, the non-specific nature of
many of the clinical features makes it imperative to
exclude other infections such as malaria, tuberculosis,
HIV infection, leishmaniasis, toxoplasmosis, hook-
worm infection, typhoid, and viral encephalitis (5). A
particular pitfall is that inappropriate antimalarial
treatment may actually reduce the fever due to HAT,
thus confounding and delaying the correct diagnosis
(5), and these two conditions may also co-exist.
Specific diagnosis at the hemolymphatic stage ideally
involves demonstration of the trypanosomes in the
peripheral blood using stained thick and thin films
(Figure 3), or in other infected tissues such as lymph
node aspirates or occasionally bone marrow (5). While
parasite detection in the blood is frequently successful
in rhodesiense infection because of the permanent para-
sitaemia, this method is very difficult in gambiense infec-
tion, in which few parasites are present in the peripher-
al circulation other than at periods of cyclic parasitaemia,
which reflects the chronicity of the disease. Therefore,
serologic tests are of crucial importance in the diagno-
sis of gambiense infection. Currently the antibody-detect-
ing card agglutination trypanosomiasis test (CATT) is
in frequent use for serological gambiense diagnosis, being
simple, easy to perform, and rapid (14).
Figure 2
Diagrammatic representation of the life cycle of Trypanosoma brucei in the human and the tsetse fly. Image credit: Alexander J. da Silva and
Melanie Moser, Centers for Disease Control Public Health Image Library.
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The key issue in HAT diagnosis and therapeutic deci-
sion making is to distinguish reliably the late encephalitic
stage of HAT from the early stage. Accurate staging of
HAT is critical because failure to treat a patient with CNS
involvement will lead inevitably to death from the disease,
yet inappropriate CNS treatment in an early-stage patient
carries a high risk of unnecessary drug toxicity (see
below). In patients with suspected late-stage disease it is
imperative to perform a lumbar puncture, which typical-
ly shows a lymphocytic pleiocytosis and raised protein
level of 40–200 mg/100 ml (5). Further, all CATT-positive
patients also need to undergo a lumbar puncture, as there
are no reliable clinical suspicion criteria for early-stage
disease. The WHO criteria for CNS involvement, and
therefore for CNS drug treatment, are demonstration of
the parasites in the CSF or a white blood cell (WBC)
count of >5/µl (15). However, these criteria have been
challenged by some investigators. Thus, in Angola and
the Ivory Coast the criterion used for CNS involvement
is 20 WBCs/µl in the CSF (16). It has also been pointed
out that concentration techniques for trypanosome
detection in the CSF vary, and that a CSF pleiocytosis
may be non-specific (17). Recently it has been shown that
detection of intrathecal IgM synthesis is a very sensitive
marker for CNS involvement in sleeping sickness (18).
The latex agglutination assay for CSF IgM quantitation
can be applied in the field and has considerable promise
for both staging CNS sleeping sickness and monitoring
the development of treatment relapses (18).
CSF PCR to detect trypanosome DNA has also been
used in the diagnosis of HAT, but considerable care must
be used in the correct choice of primers, and problems
with assay reproducibility have been documented (19).
It has recently been reported that CSF PCR has a sensi-
tivity rate of 96%, although its value for therapeutic deci-
sion making has been questioned (17). Therefore, PCR
has not yet superseded serological diagnosis and, cru-
cially, it is not readily available in field conditions. It has
recently been suggested by Lejon et al. that the WHO cri-
teria should be replaced by the presence of intrathecal
IgM synthesis or the presence of >20 WBCs/µl, inde-
pendent of the presence of trypanosomes in the CSF
(16). This author regards the presence of trypanosomes
in the CSF as compelling evidence of CNS involvement.
However, patients with gambiense disease who have try-
panosomes in the CSF and <20 WBCs/µl have been
treated successfully with pentamidine (16), so perhaps
one might speculate that there is a kind of ‘intermediate
stage’ in which the trypanosomes can cross the blood-
brain barrier without invading and damaging brain
structures at that stage. Thus there are two critical, and
not necessarily congruent, issues involved, one being the
biological definition of CNS involvement, and the other
being the ground for therapeutic choices. This lack of a
universal consensus on the operational definition of
late-stage HAT remains very problematic, but the clear
requirement is to develop robust surrogate markers to
guide therapeutic choices. These diagnostics need to be
novel, simple, and affordable.
Electroencephalogram (EEG) and sophisticated neu-
roimaging are limited to specialist centers, but both
have shown abnormalities in HAT. During the
encephalitis stage the EEG shows non-specific abnor-
malities, which correlate with the severity of the dis-
ease. Changes include at least three different types of
abnormal EEG patterns, which become normal after
Figure 3
Colored scanning electron micrograph of Trypanosoma brucei in
human blood. Image credit: Science Photo Library.
Figure 4
MRI scan (proton density) of a 13-year-old patient with CNS try-
panosomiasis 3 years after successful completion of multiple treat-
ment regimens for numerous relapses of the disease. Ventricular
enlargement (especially of the frontal horns) is seen as well as diffuse
white matter changes, which are prominent in the right frontal (see
arrow) and periventricular regions. Reproduced with permission from
Butterworth-Heinemann (5).
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clinical improvement (5). Abnormalities reported on
computed tomography scans and MRI are non-specif-
ic and not pathognomonic (Figure 4), but if available
these tests should be carried out, partly to monitor the
response to treatment, and also where the diagnosis is
in doubt or where raised intracranial pressure is pres-
ent. MRI of the brain may show diffuse asymmetric
white matter abnormalities, diffuse hyperintensities in
the basal ganglia, and ventricular enlargement (5, 20).
Overview of current treatment
The current treatment of HAT is based on four main
drugs, namely suramin, pentamidine, melarsoprol, and
eflornithine (difluoromethylornithine, or DFMO), with
nifurtimox undergoing evaluation. Table 1 summarizes
their disease spectrum, stage-specificity, route of admin-
istration, postulated mode of action, and main side-
effects (21–26). It should be appreciated that most of
these drugs were developed in the first half of the twen-
tieth century, some of them would probably not pass
current high safety standards (26), and there have been
no new registered drugs for HAT since 1981. Early-stage
disease is treated with i.v. suramin in rhodesiense disease
and with intramuscular (i.m.) pentamidine in gambiense
disease according to established treatment protocols.
Treatment is effective and prevents disease progression.
The trivalent organic arsenical melarsoprol is the only
effective drug for late-stage disease in both forms of
HAT, as the drug crosses the blood-brain barrier (5, 27).
Specific treatment regimes vary considerably among
different centers and depending on whether the infec-
tion is due to rhodesiense or gambiense. Typically, a course
of 3–4 i.v. doses are given daily over a week for a total
period of 3–4 weeks (27). Ideally, patients are then fol-
lowed up every 6 months with clinical evaluation and
CSF examination for a total of 2 years, at which point a
cure has been established if the CSF is normal. Howev-
er, this policy is very difficult to carry out in routine
practice in the field. Although about 80–90% of patients
are cured with standard treatment regimes (5), there is
evidence of increasing drug resistance, with treatment
failure rates of 30% reported among patients in North-
ern Uganda (27, 28). But the major problem with melar-
soprol treatment is that it is followed by a severe post-
treatment reactive encephalopathy (PTRE) in up to 10%
of cases, with a fatality rate of about 50% (29). Thus the
overall mortality rate from melarsoprol therapy is 5%,
which is unacceptably high (30). A prospective, ran-
domized, non-blinded trial involving 598 patients with
gambiense disease showed that the incidence of melarso-
prol-induced encephalopathy and death was reduced in
patients who were given concurrent administration of
prednisolone and melarsoprol compared with melarso-
prol therapy alone. However, this combined treatment
regime was not associated with a reduction in the inci-
dence of the other complications of PTRE or the relapse
rate after melarsoprol therapy (31). Treatment of PTRE
is focussed on treating seizures, general management of
the comatose patient with i.v. hydration, antipyretics,
steroids, and reduction of cerebral edema (5). After
Table 1
Drugs currently used for the treatment of human African trypanosomiasis
Drug Spectrum Indication Year of Route of Mode of Side-effects/
first use administration action comments
Suramin T.b. rhodesiense Stage 1 Early 1920s i.v. Evidence for inhibition of Anaphylactic shock, renal 
acute phase protein stimulation, failure, skin lesions, 
mediated by impairment of neurologic effects
receptor function and/or 
signal transduction (21)
Pentamidine T.b. gambiense Stage 1 1940 i.m. Evidence for interference with Hypotension, 
action and synthesis of polyamines hypoglycaemia, 
and selective inhibition of hyperglycaemia
parasite plasma membrane 
Ca2+-Mg2+-ATPase and Ca2+
transport (22)
Melarsoprol T.b. gambiense Stage 2 1949 i.v. Acts on trypanothione, a PTRE, cardiac arrhythmias, 
(Mel B) T.b. rhodesiense trypanosome molecule which dermatitis, agranulocytosis; 
maintains an intracellular increasing treatment failure
reducing environment (23)
Eflornithine T.b. gambiense Stage 2 1981 i.v. Irreversible inhibition of ornithine Bone marrow toxicity, 
(DFMO) decarboxylase, the key enzyme gastrointestinal effects 
in polyamine biosynthesis (24) (oral drugs), alopecia, 
seizures; drug is expensive, 
oral bioavailability not high
Nifurtimox T.b. gambiense Stage 2? 1977 Oral Evidence for interference Gastrointestinal and 
T.b. rhodesiense? with trypanothione neurologic effects; toxicity 
metabolism (25, 26) poorly documented; registered 
for Chagas disease but not 
for HAT; no standard treatment 
protocols; possible role 
in combination therapy
Table reproduced in part, and modified with permission, from Lancet Infect. Dis. (27). i.m., intramuscular.
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recovery, melarsoprol has to be restarted, possibly with
a smaller initial dose, and the course then completed (5).
A new, shorter treatment regime consisting of a 10-day
course of daily melarsoprol injections was recently
found to be comparable to the standard longer treat-
ment schedule over a period of 26 days, in terms of both
cure and complication rates, and may be increasingly
adopted in the future (32).
There has been great interest in developing safer
drugs for late-stage HAT. DFMO has been used suc-
cessfully to treat late-stage disease, especially melarso-
prol-refractory gambiense infection (33), and also
increasingly as first-line therapy, but is largely ineffec-
tive for rhodesiense infection. The problems with this
drug’s availability will be mentioned later. Nifurtimox
is the only other potential alternative treatment for
late-stage disease, but well-documented evidence of its
efficacy and safety is lacking, and its utility is more like-
ly to be in the context of combination therapy.
Neuropathogenesis
The pathologic substrate of late-stage sleeping sickness
is a meningoencephalitis in which cellular proliferation
occurs in the leptomeninges, and a diffuse perivascular
white matter infiltration consisting of lymphocytes,
plasma cells, and macrophages is prominent (5, 34).
The perivascular cuffs and adjacent parenchyma con-
tain markedly activated astrocytes and macrophages,
and the white matter contains pathognomonic moru-
lar or Mott cells, which are thought to be modified
plasma cells containing eosinophilic inclusions com-
prising IgM (34) (Figure 5). PTRE shows an exacerba-
tion of these pathologic features.
Current understanding of the highly complex patho-
genesis of sleeping sickness is based mainly on studies
carried out either on patients’ blood and CSF samples or
in experimental animal models. In both cases, correla-
tion of specific clinical features or stages with alterations
of different biochemical or immunological parameters
has often yielded interesting results, but caution must
be used in assuming a cause-and-effect relationship
between the investigation and the disease phenotype.
Care must also be used in extrapolating results obtained
in animal models to the human disease.
Alteration of cytokine levels has been detected in
patients with CNS sleeping sickness. For example, sig-
nificant elevations of IL-10 were detected in both the
plasma and CSF in both early- and late-stage rhodesiense
disease, and declined after treatment to the levels found
in uninfected control persons (35). Total, but not free,
plasma TNF-α levels were also higher in late-stage dis-
ease compared with levels obtained after treatment.
However, the source of IL-10 elevation is unclear. Simi-
lar studies in patients with gambiense infection have also
reported elevations of CSF IL-10 levels in late-stage dis-
ease, as well as a rise in IL-6 and IL-8 (36). Other abnor-
malities which have been reported in patients with CNS
HAT include very raised CSF levels of prostaglandin D2
(37), which may be related to the marked somnolence,
and raised blood and CSF endotoxin levels that may
also contribute to the CNS pathology (38).
Several possible causes of PTRE have been suggested,
including subcurative chemotherapy, abnormal im-
mune responses to glial cell–attached antigens released
from killed parasites following melarsoprol treatment,
immune complex deposition, arsenical toxicity, and
autoimmune mechanisms (39–42). PTRE has been
studied in a reproducible mouse model that mirrors
many of the pathologic features of the disease in hu-
mans (43). Injection of Trypanosoma brucei into mice via
the intraperitoneal route leads to a chronic infection in
which the parasites are detectable in the CNS after 21
days. If the drug berenil (diminazene aceturate), which
does not cross the blood-brain barrier and therefore
clears the parasites from the extravascular compart-
ment but not the CNS, is given 21–28 days after infec-
tion, the mice develop a severe post-treatment menin-
goencephalitis, which persists after the parasitemic
phase is over. This condition shows strong pathologic
Figure 5
Neuropathology of CNS human African trypanosomiasis. (a) Late-
stage disease in a patient who died 3–5 months after first injection
of melarsoprol. Many large astrocytes are located in white matter.
Stained for glial fibrillary acidic protein by immunoperoxidase. Orig-
inal magnification, ×400. (b) Morular cells (indicated by arrows)
observed in the brain of a patient with CNS trypanosomiasis who
had not received melarsoprol. Morular cells are plasma cells filled
with immunoglobulin. H&E stain. Original magnification, ×400. (c)
PTRE in a patient dying 9 days after receiving melarsoprol. Ischaemic
cell changes (indicated by arrows) are seen in neurons in the hip-
pocampus. H&E stain. Original magnification, ×250. (d) PTRE with
acute haemorrhagic leukoencephalopathy in a patient 9 days after
receiving melarsoprol. There is fibrinoid necrosis in an arteriole (indi-
cated by arrow) and focal haemorrhage in the pons. Martius scarlet
blue stain. Original magnification, ×250. Reproduced with permis-
sion from Neuropathol. Appl. Neurobiol. (34).
Downloaded July 30, 2014 from The Journal of Clinical Investigation. doi:10.1172/JCI21052.
502 The Journal of Clinical Investigation | February 2004 | Volume 113 | Number 4
similarity to PTRE in humans. A consistent observa-
tion in this model is that astrocytes are activated
14–21 days after infection and prior to the develop-
ment of the inflammatory response (43, 44), and that
transcripts for several cytokines such as TNF-α, IL-1,
IL-4, IL-6 and IFN-γ can be detected in the brain at this
time (44, 45). Early astrocyte activation is therefore
likely to be of central importance in generating the
CNS inflammatory response.
Different types of drug have been shown to modulate
the inflammatory response in this mouse model. The
trypanostatic drug DFMO has the ability to prevent
the development of PTRE or ameliorate it once it is
established in terms of greatly reducing both the neu-
ropathology and the degree of astrocyte activation (46).
The immunosuppressant drug azathiaprine can pre-
vent but not cure PTRE (47), and the non-peptide Sub-
stance P (SP) antagonist RP-67,580 has been shown to
significantly ameliorate both the neuroinflammatory
reaction and the level of astrocyte activation (48).
Although this showed that SP plays a role in generat-
ing the inflammatory response in this PTRE, recent evi-
dence has shown that this is complex, since infected SP
knockout mice show a novel phenotype in which the
clinical and neuroinflammatory responses were disso-
ciated with evidence of alternative tachykinin receptor
usage (49). There is also evidence for the role of various
chemokines such as macrophage inflammatory pro-
tein (MIP)-2, RANTES, and MIP-1α produced by astro-
cytes, microglia, and T cells early in the CNS infection
in a rat model (50). It should also be pointed out that
in both human disease and animal models the cellular
sources of these cytokines and neuropeptides are some-
times not known and are only inferred, with multiple
stimuli for their secretion likely.
It is clear that macrophage activation by both para-
site components and host-derived cytokines is central
to HAT pathogenesis. Both VSG and GPI anchors are
known to be potent macrophage activators (51, 52), as
is IFN-γ, which itself may derive from several sources,
including CD4+ and NK cells (53). A molecule called
trypanosome-derived lymphocyte triggering factor has
been described in mouse and rat models (54, 55). This
molecule triggers the CD8+ T cell to produce IFN-γ,
which both activates macrophages and apparently has
growth-enhancing effects on trypanosomes (54, 56).
The overall picture that is now emerging is a highly
complex network of cytokine-brain interactions, with
early astrocyte activation, macrophage activation, and,
at least in animal models, an inflammatory cytokine
response being prominent features (43, 52, 57, 58)
(summarized schematically in Figure 6).
Figure 6
Schematic representation of possible immunopathologic pathways leading to brain dysfunction in late-stage human African trypanosomia-
sis. Concepts are based on a combination of human and animal model data and ideas, particularly from refs. 43, 48, 51, 53, and 56. Cytokines
shown in red probably have important roles in neuropathogenesis. The schematic emphasizes the central importance of early astrocyte acti-
vation, cytokine responses, and macrophage activation. One should note that there are likely to be multiple factors acting together to pro-
duce brain damage and also multiple potential sources of different cytokines. Tltf, trypanosome-derived lymphocyte triggering factor.
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Prospects for CNS sleeping sickness
Advances in this field are likely to be made in several
areas. The increasing use of animal models, including
host and parasite gene knockouts, should help unrav-
el the complex neuropathogenesis of sleeping sickness,
in particular the role of specific neuropeptides and the
importance of the balance of proinflammatory versus
counterinflammatory cytokines. But such studies will
need to be interpreted in the context of sophisticated
analyses of the serum and CSF of human subjects.
Physicians need to reach a consensus as to what does
and does not define late-stage HAT, and to be able to
use reliable surrogate markers that will allow them to
make rational therapeutic decisions, in particular
when embarking on a treatment modality that cur-
rently has an overall mortality rate of 5%. There is a
pressing need to developing a quick, easy to perform,
reliable, and cheap diagnostic test that can be used in
the field to diagnose and, crucially, to stage both gam-
biense and rhodesiense disease.
Control of sleeping sickness will require: (a) continu-
ing and improved case surveillance with screening of
humans in at-risk areas and also of domestic cattle; this
will require both political will and stability and signifi-
cantly increased funding to improve the screening infra-
structure; (b) better treatment of human disease and of
animal reservoirs; and (c) increased public health meas-
ures to significantly decrease, and ultimately eradicate,
human/tsetse fly contact through the use of, for exam-
ple, increasingly sophisticated fly traps in infected areas,
spraying of insecticides, and molecular genetic ap-
proaches such as the replacement of susceptible insect
phenotypes with their engineered refractory counter-
parts to result in decreased HAT transmission (7).
The unacceptable toxicity of the currently available
drugs for HAT underpins the urgency of developing
more effective and safer drug regimes. A safe drug that is
effective in the treatment of CNS HAT would dramati-
cally change the control and management of sleeping
sickness, as it would obviate the current difficulties of
staging with CSF analysis. However, in reality no new
drugs are likely to appear within the next 5 years, and
even that may be overly optimistic. An effective oral drug
is required for early-stage disease, but several recent can-
didate compounds have been abandoned because of
unacceptable toxicity or lack of efficacy. The best, indeed
only, candidate is DB 289, which is a diamidine deriva-
tive and the oral prodrug of an active form called DB 75
(27). A phase IIa clinical trial with DB 289 has just been
completed, with good results in terms of safety and effi-
cacy, but the drug will probably only be effective in early-
stage disease (C. Burri, personal communication). A
phase IIb multi-center, randomized, controlled trial of
80 patients with DB 289 is currently under way (C. Burri,
personal communication). DFMO is effective for late-
stage gambiense disease and is far less toxic than melar-
soprol, but it became an orphan drug, as it was expensive
and non-profitable for pharmaceutical companies. Only
as a result of the remarkable efforts of Médecins Sans
Frontières, working with the WHO and the drug com-
panies Aventis Pharma and Bristol-Myers, who had
developed a renewed interest in this drug, is DFMO cur-
rently available for HAT treatment in Africa (59).
Another avenue of treatment is the use of combination
therapy in order to increase efficacy, decrease toxicity,
and delay the onset of drug resistance. Drug combina-
tions also have the potential to solve the problems of
complexity and high costs of current alternatives to
melarsoprol. This approach can also be tested in the
mouse model of HAT, which can provide valuable clues
for novel treatment strategies (43). Current regimes of
combination therapy which can be explored in humans
with CNS HAT disease include DFMO/melarsoprol,
melarsoprol/nifurtimox, and DFMO/nifurtimox. The
latter regime, having shown lower toxicity in limited clin-
ical studies, is currently under evaluation in a controlled
clinical trial (G. Priotto, personal communication). A
major hope for the future is that the morbidity and mor-
tality from PTRE can be reduced from their current high
level. Recent advances in our understanding of normal
blood-brain barrier function and permeability have
raised the possibility that existing or new trypanocidal
drugs may be modified so as to cross the blood-brain
barrier, thereby opening up a new therapeutic dimension
for CNS sleeping sickness. A further approach is to mod-
ify dose regimes of currently available drugs, as has been
the case with melarsoprol (32). More targeted approach-
es to treatment should also be possible, such as adjunct
therapy of standard drug regimes with humanized neu-
ropeptide antagonists to specifically block key compo-
nents of the inflammatory response.
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